Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG
(Thomson Reuters ONE) -
Press Release
Lund February 13, 2017
Enzymatica enters into partnership agreement with STADA Arzneimittel AG
The agreement grants STADA exclusive rights to sell, market and distribute
Enzymatica's common cold product ColdZyme® in Germany. Stada is a global
pharmaceutical company, headquartered in Germany, with a strong presence in
Europe and leading positions in the cough and cold category in Germany, UK, and
Russia.
"We are very pleased to have signed the agreement with STADA as our marketing,
sales, and distribution partner for Germany, particularly since Germany is the
single largest market for over-the-counter products in Europe. This agreement
confirms the commercial potential for ColdZyme outside of Scandinavia, and
endorses the interest in Enzymatica's technology platform", says Fredrik
Lindberg, CEO of Enzymatica.
"We are very excited about our agreement with Enzymatica to help maximize the
ColdZyme opportunity in Germany. ColdZyme's unique product offering is different
to traditional cold therapies and is a perfect fit to our existing portfolio as
well as to our strategy of growing our branded business on the back of
launching innovative, new products", says Wolfram Gollin, Head of Marketing
STADA GmbH.
The company's first product, ColdZyme, is a unique mouth spray for use against
the common cold.
In Europe, ColdZyme is directly marketed and sold by Enzymatica in Sweden,
Norway and Denmark and sold through marketing and sales partners in Spain,
Finland, Iceland and Greece. In the UK, the ColdZyme business is handled by a
sales agent.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg(at)enzymatica.com
This information is information that Enzymatica AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was submitted
for publication, through the agency of the contact person set out above, at
0830 CET on February 13, 2017.
Enzymatica
Enzymatica is a life science company who develops and sells medical device
products against infectious-related diseases. Over a short period the company
has developed a unique oral spray for colds, ColdZyme®, and launched it on eight
markets. The product has become one of the leading articles for colds in Swedish
pharmacies. Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical markets through
well-established partners. The company is headquartered in Lund, Sweden and is
listed on Nasdaq First North. For more information, please visit
www.enzymatica.com.
Enzymaticas Certified Adviser is Erik Penser Bank.
Stada Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed globally leading generics producer
with a traditionally strong presence in Europe and especially Germany. STADA is
internationally-oriented and the Top 5 markets are Germany, Russia, UK, Italy
and Spain. STADA generated Group sales of ? 2.115,1 million in 2015 and had
10,532 employees worldwide. Stada has its headquarters in Bad Vilbel, Germany.
For more information visit www.stada.com
Enzymatica Press Release Stada:
http://hugin.info/160850/R/2077926/781795.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.02.2017 - 08:30 Uhr
Sprache: Deutsch
News-ID 523604
Anzahl Zeichen: 4073
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG"
steht unter der journalistisch-redaktionellen Verantwortung von
Enzymatica AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
